Since its foundation in 2011, GENCURIX has continued to grow into a company specializing in biomolecule diagnosis through active and steady accumulation of R&D capabilities and product development to realize a healthier and better life for patients.
We are constantly striving to contribute to improving the quality of life of patients by providing optimal treatment at a minimum cost through customized diagnosis.
Focusing on the development of diagnostic products for cancer patients, we have developed a variety of cancer diagnostic products, including Korea's first breast cancer prognosis diagnosis kit 'GenesWell BCT' and the next-generation analysis technology 'GenesWell dEGFR Mutation Test'.
In the future, we plan to expand cancer types such as colon cancer and liver cancer to establish a product pipeline.